Biomarker progressions explain higher variability in stage‐specific cognitive decline than baseline values in Alzheimer disease. Issue 6 (8th July 2014)

• Record Type: Journal Article
• Authors: Dodge, Hiroko H.; Zhu, Jian; Harvey, Danielle; Saito, Naomi; Silbert, Lisa C.; Kaye, Jeffrey A.; Koeppe, Robert A.; Albin, Roger L.
• Is Part Of: Alzheimer's & dementia. Volume 10:Issue 6(2014)
• Page Start: 690
• Page End: 703
• Publication Date: 2014-07-08
• Subjects: ADNI -- Cognitive declines -- Biomarker -- Biomarker progressions -- ADNI‐mem -- ADNI‐exe -- MCI -- FDG‐PET -- MRI volume; Alzheimer's disease -- Periodicals; Alzheimer Disease -- Periodicals; Dementia -- Periodicals; Démence; Maladie d'Alzheimer; Périodique électronique (Descripteur de forme); Ressource Internet (Descripteur de forme); 616.83
• DOI: 10.1016/j.jalz.2014.04.513
• Languages: English
• ISSNs: 1552-5260

Abstract

Abstract: Background: It is unknown which commonly used Alzheimer disease (AD) biomarker values—baseline or progression—best predict longitudinal cognitive decline. Methods: 526 subjects from the Alzheimer's Disease Neuroimaging Initiative (ADNI). ADNI composite memory and executive scores were the primary outcomes. Individual‐specific slope of the longitudinal trajectory of each biomarker was first estimated. These estimates and observed baseline biomarker values were used as predictors of cognitive declines. Variability in cognitive declines explained by baseline biomarker values was compared with variability explained by biomarker progression values. Results: About 40% of variability in memory and executive function declines was explained by ventricular volume progression among mild cognitive impairment patients. A total of 84% of memory and 65% of executive function declines were explained by fluorodeoxyglucose positron emission tomography (FDG‐PET) score progression and ventricular volume progression, respectively, among AD patients. Conclusions: For most biomarkers, biomarker progressions explained higher variability in cognitive decline than biomarker baseline values. This has important implications for clinical trials targeted to modify AD biomarkers.